drugset

drugset / Trial / NCT01423903

Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer

NCT01423903 ↗

Phase 1 Completed 45 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether OPB-51602 is safe and tolerable when given daily by mouth to subjects with advanced solid tumors.

Timeline

Start: 2010-02
Primary completion: 2013-04
Completion: 2013-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	OPB-51602	Unknown	—	Oral

Indications